The Trump administration has secured a groundbreaking agreement with pharmaceutical giants Eli Lilly and Novo Nordisk that will dramatically reduce prices for GLP-1 medications while expanding Medicare coverage for obesity treatment for the first time. The deal, announced Thursday, brings some monthly drug costs down to approximately $250 and establishes price caps for future medications, marking a significant shift in healthcare policy that could pressure insurers to revisit restrictive coverage rules that have limited patient access to these transformative treatments.
about Trump Cuts GLP-1 Drug Prices, Expands Medicare Coverage
LLY
Trump’s Ozempic Price Comments Hit Novo Nordisk, Lilly Shares
Pharmaceutical giants Novo Nordisk and Eli Lilly faced immediate market pressure after former President Donald Trump declared that the price of diabetes drug Ozempic could plummet to just $150 monthly—a dramatic reduction from its current $1,000 list price. Trump’s Oval Office comments specifically targeted what he called ‘the fat loss drug’ and suggested similar pricing for Lilly’s competing treatments Mounjaro and Zepbound, threatening the dominant position of both companies in a market projected to exceed $95 billion by 2030.
about Trump's Ozempic Price Comments Hit Novo Nordisk, Lilly SharesMarket Jitters: Bank Stocks Fall, Credit Fears Deepen
US financial markets face renewed pressure as bank stocks tumble amid deepening credit concerns, with Zions Bancorp and Western Alliance leading a sector-wide selloff following fraud allegations. Simultaneously, pharmaceutical giants Novo Nordisk and Eli Lilly decline after former President Trump’s comments about potential Ozempic price reductions, while the auto industry anticipates tariff relief on imported parts. The market turbulence reflects broader anxieties as Treasuries extend their rally and the dollar heads for its largest weekly drop since July.
about Market Jitters: Bank Stocks Fall, Credit Fears DeepenTop 5 Dividend ETFs for Income & Growth: SCHD, VIG, DGRO, VYM, SDY
For investors seeking both reliable income streams and capital appreciation, dividend-focused exchange-traded funds (ETFs) offer a compelling solution. These investment vehicles provide passive, regular income through carefully curated portfolios of companies with strong dividend histories and above-average yields. We examine five top-performing dividend ETFs that span different strategies—from high-yield approaches to consistent dividend growth—all showing impressive recovery since April lows and presenting clear pathways for future gains.
about Top 5 Dividend ETFs for Income & Growth: SCHD, VIG, DGRO, VYM, SDYSPY ETF: 89.72% Gain in 5 Years Shows S&P 500 Power
The SPDR S&P 500 ETF (SPY) has delivered an impressive 89.72% total return over the past five years, transforming a $10,000 investment into $18,972. This remarkable performance underscores the enduring power of broad-market, low-cost investing through exchange-traded funds, demonstrating why SPY remains a cornerstone for investors seeking diversified exposure to America’s top companies without the complexities of stock-picking or market-timing.
about SPY ETF: 89.72% Gain in 5 Years Shows S&P 500 PowerPfizer Avoids Tariffs, Cuts Drug Prices in Trump Deal
In a landmark move that sent shockwaves through global pharmaceutical markets, Pfizer has secured a crucial agreement with the Trump administration to avoid tariffs by committing to lower drug prices for American consumers. The deal, which includes a massive $70 billion domestic investment pledge, represents a significant victory for the pharmaceutical giant and sets a new precedent for industry pricing strategies. With competitors Eli Lilly and Merck expected to follow suit, this development signals a fundamental shift in how pharmaceutical companies navigate trade policy while addressing public pressure over medication costs.
about Pfizer Avoids Tariffs, Cuts Drug Prices in Trump DealInsiders Bet Big on These 3 Stocks for 2025
Corporate insiders are sending a powerful signal by aggressively buying shares of their own companies. Three stocks in particular—Eli Lilly, Matador Resources, and Eastman Chemical—are seeing exceptional insider activity despite recent price declines. This pattern historically precedes abnormal returns, making these moves worth watching closely.
about Insiders Bet Big on These 3 Stocks for 2025U.S. Stock Futures Rise Ahead of December CPI Inflation Report
U.S. stock futures are rising ahead of the December CPI inflation report, expected to show a slight increase to 2.8%, which may impact market sentiment. Strong earnings from major companies are boosting optimism, but concerns linger about progress toward the Federal Reserve’s 2% inflation target.
about U.S. Stock Futures Rise Ahead of December CPI Inflation ReportAsian Stocks Mixed Ahead of Key US Inflation Data Release
Asian stocks showed mixed results as investors awaited key U.S. inflation data that could impact Federal Reserve rate cuts. Japan’s Nikkei rose 0.1%, while South Korea’s Kospi gained 0.2% amid political turmoil. In the U.S., the S&P 500 edged up 0.1%, driven by lower-than-expected wholesale inflation, although concerns over rising Treasury yields and disappointing earnings from major companies like Eli Lilly weighed on market sentiment.
about Asian Stocks Mixed Ahead of Key US Inflation Data ReleaseWall Street Gains Amid Mixed Earnings and Falling Crude Oil Prices
U.S. stocks mostly rose following positive wholesale inflation data, with the S&P 500 up 0.1% and the Dow Jones gaining 221 points. However, Eli Lilly’s 6.6% drop and declines in several Big Tech stocks limited gains. Treasury yields stabilized, impacting market dynamics as earnings season begins.
about Wall Street Gains Amid Mixed Earnings and Falling Crude Oil PricesMarket Update Applied Digital Soars Eli Lilly and Signet Jewelers Struggle
Applied Digital shares surged after Macquarie Asset Management announced a potential $5 billion investment in its HPC data centers. In contrast, Eli Lilly’s stock fell nearly 7% following a lowered revenue forecast for 2024, while Boeing faced challenges with declining plane deliveries, leading to a 2% drop in its shares. H&E Equipment’s stock more than doubled after a $4.8 billion acquisition by United Rentals, and Signet Jewelers saw a 22% plunge due to weak holiday sales and lowered guidance.
about Market Update Applied Digital Soars Eli Lilly and Signet Jewelers StruggleWall Street Gains Amid Positive Inflation Data Despite Eli Lilly Decline
Most U.S. stocks rose on Tuesday following positive inflation data, with the S&P 500 up 0.1% and the Dow Jones Industrial Average gaining 164 points, or 0.4%. However, declines in Eli Lilly and other key stocks limited further gains, leaving the Nasdaq composite down 0.1%.
about Wall Street Gains Amid Positive Inflation Data Despite Eli Lilly Decline